FindTrial
Sign In

STAT3 Inhibitor WP1066

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center, Northwestern University

Conditions

Glioblastoma, IDH-WildtypeMGMT-Unmethylated GlioblastomaMetastatic Malignant Neoplasm in the BrainMetastatic MelanomaRecurrent Brain NeoplasmRecurrent GlioblastomaRecurrent Malignant Glioma

Phase 1

STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
CompletedNCT01904123
M.D. Anderson Cancer CenterMetastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Recurrent Brain Neoplasm +2
Start: 2018-07-13End: 2022-03-16Updated: 2022-03-23

Phase 2

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
RecruitingNCT05879250
Northwestern UniversityGlioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Start: 2024-05-22End: 2028-12-27Target: 39Updated: 2026-07-22

Related Papers

Review of Patents for Anticancer Agents Targeting Adenosine Monophosphate-Activated Protein Kinase.
2023-08-161 citations
Abstract 4799: Inhibition of STAT3 in pancreatic ductal adenocarcinoma and immunotherapeutic implications
Cancer Research2019-07-01
Abstract 4799: Inhibition of STAT3 in pancreatic ductal adenocarcinoma and immunotherapeutic implications
Experimental and Molecular Therapeutics2019-07-01
656. Effects of STAT3 Inhibition on the Innate Immune Response to OV Therapy
Molecular Therapy2016-05-01